glp-1 migraines medications and how they may change how we treat headaches in pseudotumor cerebri patients #glp1 #pseudotumorcerebri #hydrocephalus #headaches #migraine New Findings Suggest GLP-1s May

[6] Tirzepatide (Mounjaro): up to 15 mg once weekly for type 2 diabetes, and up to 15 mg once weekly for chronic weight management (marketed as Tirzepatide)

Compare that to the STEP 1 extension data, where participants regained 11.6 percentage points within 52 weeks of stopping semaglutide without any structured dietary intervention

They also show promise for the treatment of many inflammatory diseases including asthma and inflammatory bowel disorders like Crohns disease and ulcerative colitis Diagram showing food stimulating the release of GLP-1 into the intestine and its effects on the brain, stomach and pancreas Importance In 2023 GLP-1 based drugs was named breakthrough of the year by Science , a prestigious American journal

2010;60:e1217

Nutrient interactions: A 2025 study looked at how nutrient levels of common vitamins interacted with the risk of restless leg syndrome

doi: 10.1016/j.diabres.2015.12.003